section name header

Interacting Drugs

OBJECT DRUGS

Beta-blockers (CYP2D6 Substrates):

PRECIPITANT DRUGS

Enzyme Inhibitors (CYP2D6):


* Propoxyphene (Darvon) was withdrawn from the US market.


Comment:

Inhibitors of CYP2D6 can increase the concentration of beta-blockers, potentially resulting in bradycardia, hypotension or heart failure. Rapid metabolizers of CYP2D6 (over 90% of the population) will be at the greatest risk. Note that because terbinafine has an extraordinarily long terminal half-life, the inhibitory effect of terbinafine on CYP2D6 may last for many weeks after terbinafine is discontinued.


Class 3: Assess Risk & Take Action if Necessary